Activated Leukocyte Cell Adhesion Molecule Is a Marker for Thyroid Carcinoma Aggressiveness and Disease-Free Survival

Chaker, Seham; Kak, Ipshita; MacMillan, Christina; Ralhan, Ranju; Walfish, Paul G.

doi:10.1089/thy.2012.0405

Cited by 8 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Miccichè et al [110] has reported, in early findings, that thyroid cancer expressed ALCAM on the membrane and cytoplasmic region and is able to shed it from the cell membrane [110]. Total ALCAM in poorly differential thyroid tumours was found to be markedly lower than those with well/moderately differentiated tumours, and the reduction was associated with distant metastasis and shortened survival (6 years vs. 13.7 years, low vs. high cytoplasmic ALCAM, respectively) [74].…”

Section: Thyroid Cancersmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Yang

Sanders

Dou

et al. 2021

Cancers

View full text Add to dashboard Cite

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a cell adhesion protein that is found in multiple cell types. ALCAM has multiple and diverse roles in various physiological and pathological conditions, including inflammation and cancer. There has been compelling evidence of ALCAM’s prognostic value in solid cancers, indicating that it is a potential therapeutic target. The present article overviews the recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections in cancer and therapeutic values.

show abstract

Section: Thyroid Cancersmentioning

confidence: 99%

“…Total ALCAM in poorly differential thyroid tumours was markedly lower than those with well/moderately differentiated tumours, and the reduction was associated with distant metastasis and shortened survival. [74] Prostate cancer…”

Section: Tcga Analysis and Cell Workmentioning

confidence: 99%

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Yang

Sanders

Dou

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Carbotti et al also identified serum ALCAM as a potential biomarker of epithelial ovarian cancer in type II tumors. There are similar findings in other tumor types.…”

Section: Resultsmentioning

confidence: 99%

Whole‐Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This is mainly due to the malfunctioning in CAMs, which has been shown to play an important role in cancer progression [33] and disrupting important signal-transduction pathways [34]. Specifically, CAMs have been shown to be involved in brain [35], bladder [36], breast [37], liver [38], lung [39] and thyroid [40] cancer; the cancer data sets where the proposed system found the CAM pathway as significantly activated.…”

Section: Discussionmentioning

confidence: 99%

Bayesian Pathway Analysis of Cancer Microarray Data

et al. 2014

View full text Add to dashboard Cite

High Throughput Biological Data (HTBD) requires detailed analysis methods and from a life science perspective, these analysis results make most sense when interpreted within the context of biological pathways. Bayesian Networks (BNs) capture both linear and nonlinear interactions and handle stochastic events in a probabilistic framework accounting for noise making them viable candidates for HTBD analysis. We have recently proposed an approach, called Bayesian Pathway Analysis (BPA), for analyzing HTBD using BNs in which known biological pathways are modeled as BNs and pathways that best explain the given HTBD are found. BPA uses the fold change information to obtain an input matrix to score each pathway modeled as a BN. Scoring is achieved using the Bayesian-Dirichlet Equivalent method and significance is assessed by randomization via bootstrapping of the columns of the input matrix. In this study, we improve on the BPA system by optimizing the steps involved in “Data Preprocessing and Discretization”, “Scoring”, “Significance Assessment”, and “Software and Web Application”. We tested the improved system on synthetic data sets and achieved over 98% accuracy in identifying the active pathways. The overall approach was applied on real cancer microarray data sets in order to investigate the pathways that are commonly active in different cancer types. We compared our findings on the real data sets with a relevant approach called the Signaling Pathway Impact Analysis (SPIA).

show abstract

Activated Leukocyte Cell Adhesion Molecule Is a Marker for Thyroid Carcinoma Aggressiveness and Disease-Free Survival

Cited by 8 publications

References 35 publications

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Whole‐Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme

Bayesian Pathway Analysis of Cancer Microarray Data

Contact Info

Product

Resources

About